HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Small molecule-induced protein degradation is an attractive strategy for the development of chemical probes. One method for inducing targeted protein degradation involves the use of PROTACs, heterobifunctional molecules that can recruit specific E3 ligases to a desired protein of interest. PROTACs have been successfully used to degrade numerous proteins in cells, but the peptidic E3 ligase ligands used in previous PROTACs have hindered their development into more mature chemical probes or therapeutics. We report the design of a novel class of PROTACs that incorporate small molecule VHL ligands to successfully degrade HaloTag7 fusion proteins. These HaloPROTACs will inspire the development of future PROTACs with more drug-like properties. Additionally, these HaloPROTACs are useful chemical genetic tools, due to their ability to chemically knock down widely used HaloTag7 fusion proteins in a general fashion.

[1]  A. Ransick,et al.  Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation* , 2003, Molecular & Cellular Proteomics.

[2]  Lisa M. Ryno,et al.  Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. , 2013, Journal of the American Chemical Society.

[3]  W. L. Jorgensen,et al.  Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.

[4]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Lisa M. Ryno,et al.  Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. , 2013, Cell reports.

[6]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[7]  E. Choi,et al.  Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool , 2007, Chembiochem : a European journal of chemical biology.

[8]  Yukihiro Itoh,et al.  Development of target protein-selective degradation inducer for protein knockdown. , 2011, Bioorganic & medicinal chemistry.

[9]  E. Choi,et al.  Impact of linker length on the activity of PROTACs. , 2011, Molecular bioSystems.

[10]  Thomas B. Sundberg,et al.  Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins , 2012, Chembiochem : a European journal of chemical biology.

[11]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[12]  T. Aoyagi,et al.  Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. , 1976, The Journal of antibiotics.

[13]  L. Banaszynski,et al.  A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules , 2006, Cell.

[14]  Michael A. Koldobskiy,et al.  Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.

[15]  R. Deshaies,et al.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer , 2008, Oncogene.

[16]  Julien Michel,et al.  Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.

[17]  K. Sakamoto.  Protacs for Treatment of Cancer , 2010, Pediatric Research.

[18]  Andreas Thomann,et al.  Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. , 2012, Chemistry & biology.

[19]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[20]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[21]  Marjeta Urh,et al.  HaloTag: a novel protein labeling technology for cell imaging and protein analysis. , 2008, ACS chemical biology.

[22]  Yukihiro Itoh,et al.  Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. , 2012, Bioorganic & medicinal chemistry letters.

[23]  Junko Yaegashi,et al.  Precise control of protein concentration in living cells. , 2010, Angewandte Chemie.

[24]  C. Contag,et al.  Chemical control of protein stability and function in living mice , 2008, Nature Medicine.

[25]  K. Wood,et al.  HaloTag7: a genetically engineered tag that enhances bacterial expression of soluble proteins and improves protein purification. , 2009, Protein expression and purification.

[26]  T. Corson,et al.  Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs , 2013, Proceedings of the National Academy of Sciences.

[27]  C. Crews,et al.  Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.

[28]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Banaszynski,et al.  Conditional control of protein function , 2006, Chemistry & biology.

[30]  Chad J. Miller,et al.  A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.

[31]  E. Choi,et al.  Two‐Headed PROTAC: An Effective New Tool for Targeted Protein Degradation , 2010, Chembiochem : a European journal of chemical biology.

[32]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[33]  T. Corson,et al.  Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature Chemical Biology.

[34]  Corey W. Liu,et al.  Small molecule displacement of a cryptic degron causes conditional protein degradation , 2011, Nature chemical biology.

[35]  S. Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[36]  Minoru Ishikawa,et al.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.

[37]  Yukihiro Itoh,et al.  Specific degradation of CRABP‐II via cIAP1‐mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein , 2011, FEBS letters.

[38]  Dennis L. Buckley,et al.  Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. , 2014, Angewandte Chemie.

[39]  C. Crews,et al.  Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. , 1999, Bioorganic & medicinal chemistry letters.